Question 4 Protex is a startup company that was developing a new antiviral drug therapy. Protex just reported a successful completion to Phase I trials. It is now going to launch Phase II trials. Given the following assumptions, what was the net present value of the new therapy at the start of Phase II trials? . Cost of Phase II trials is $11 million (Assume timing of cash flows is at end of year 2) Likelihood of Passing Phase II trials is 65% . Cost of Phase III trials is $24 million (Assume timing of cash flows is at end of year 5) Likelihood of Passing Phase III trials is 75% .NPV of commercialization at end of year 5 is $115 million • Discount rate is 10% . Express your answer in $millions to two decimal places e.g. -$35.12 should be expressed as -35.12 Your Answer: Answer

Essentials Of Investments
11th Edition
ISBN:9781260013924
Author:Bodie, Zvi, Kane, Alex, MARCUS, Alan J.
Publisher:Bodie, Zvi, Kane, Alex, MARCUS, Alan J.
Chapter1: Investments: Background And Issues
Section: Chapter Questions
Problem 1PS
icon
Related questions
Question

9

Question 4
Protex is a startup company that was developing a new antiviral drug therapy. Protex
just reported a successful completion to Phase I trials. It is now going to launch
Phase II trials. Given the following assumptions, what was the net present value of
the new therapy at the start of Phase II trials?
. Cost of Phase II trials is $11 million (Assume timing of cash flows is at end of
year 2)
Likelihood of Passing Phase II trials is 65%
. Cost of Phase III trials is $24 million (Assume timing of cash flows is at end of
year 5)
. Likelihood of Passing Phase III trials is 75%
. NPV of commercialization at end of year 5 is $115 million
. Discount rate is 10%
Express your answer in $millions to two decimal places e.g. -$35.12 should be
expressed as-35.12
Your Answer:
Answer
Transcribed Image Text:Question 4 Protex is a startup company that was developing a new antiviral drug therapy. Protex just reported a successful completion to Phase I trials. It is now going to launch Phase II trials. Given the following assumptions, what was the net present value of the new therapy at the start of Phase II trials? . Cost of Phase II trials is $11 million (Assume timing of cash flows is at end of year 2) Likelihood of Passing Phase II trials is 65% . Cost of Phase III trials is $24 million (Assume timing of cash flows is at end of year 5) . Likelihood of Passing Phase III trials is 75% . NPV of commercialization at end of year 5 is $115 million . Discount rate is 10% Express your answer in $millions to two decimal places e.g. -$35.12 should be expressed as-35.12 Your Answer: Answer
Expert Solution
steps

Step by step

Solved in 2 steps

Blurred answer
Knowledge Booster
Valuing Decision
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, finance and related others by exploring similar questions and additional content below.
Similar questions
  • SEE MORE QUESTIONS
Recommended textbooks for you
Essentials Of Investments
Essentials Of Investments
Finance
ISBN:
9781260013924
Author:
Bodie, Zvi, Kane, Alex, MARCUS, Alan J.
Publisher:
Mcgraw-hill Education,
FUNDAMENTALS OF CORPORATE FINANCE
FUNDAMENTALS OF CORPORATE FINANCE
Finance
ISBN:
9781260013962
Author:
BREALEY
Publisher:
RENT MCG
Financial Management: Theory & Practice
Financial Management: Theory & Practice
Finance
ISBN:
9781337909730
Author:
Brigham
Publisher:
Cengage
Foundations Of Finance
Foundations Of Finance
Finance
ISBN:
9780134897264
Author:
KEOWN, Arthur J., Martin, John D., PETTY, J. William
Publisher:
Pearson,
Fundamentals of Financial Management (MindTap Cou…
Fundamentals of Financial Management (MindTap Cou…
Finance
ISBN:
9781337395250
Author:
Eugene F. Brigham, Joel F. Houston
Publisher:
Cengage Learning
Corporate Finance (The Mcgraw-hill/Irwin Series i…
Corporate Finance (The Mcgraw-hill/Irwin Series i…
Finance
ISBN:
9780077861759
Author:
Stephen A. Ross Franco Modigliani Professor of Financial Economics Professor, Randolph W Westerfield Robert R. Dockson Deans Chair in Bus. Admin., Jeffrey Jaffe, Bradford D Jordan Professor
Publisher:
McGraw-Hill Education